Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

By | January 20, 2023
A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.